Zou Liyun, Wu Yuzhang, Pei Li, Zhong Daping, Gen Miao, Zhao Tingting, Wu Jiehong, Ni Bing, Mou Zhirong, Han Junfeng, Chen Yongwen, Zhi Yi
Institute of Immunology of PLA, Third Military Medical University, Chongqing 400038, PR China.
Leuk Res. 2005 Dec;29(12):1387-91. doi: 10.1016/j.leukres.2005.04.021. Epub 2005 Jun 3.
The immune system plays an important role in the treatment of chronic myeloid leukemia (CML). Identification of leukemia-associated antigens (LAAs) eliciting an immune response in patients is a prerequisite for specific immunotherapy of CML. To identify new LAAs in CML, We utilized a novel approach based serology and proteomics technologies. LAAs were identified by comparing the reactivity of proteins resolved by 2-DE with sera from CML patients and healthy donors. Several new LAAs were identified including alpha enolase, aldolase A, HSP70 protein8, beta-tubulin and tropomyosin isoforms. Although, the functions of these identified proteins in CML need further investigation, the detection of autoantibodies in CML may have value on CML screening, diagnosis, or follow-up. Additionally, identification of LAAs in CML may also be of vital importance in antigen-based immunotherapy.
免疫系统在慢性粒细胞白血病（CML）的治疗中发挥着重要作用。识别能在患者体内引发免疫反应的白血病相关抗原（LAA）是CML特异性免疫治疗的先决条件。为了识别CML中的新LAA，我们采用了一种基于血清学和蛋白质组学技术的新方法。通过比较二维电泳分离的蛋白质与CML患者和健康供体血清的反应性来鉴定LAA。鉴定出了几种新的LAA，包括α烯醇化酶、醛缩酶A、热休克蛋白70、β微管蛋白和原肌球蛋白异构体。虽然这些已鉴定蛋白质在CML中的功能需要进一步研究，但检测CML中的自身抗体可能对CML的筛查、诊断或随访具有价值。此外，识别CML中的LAA在基于抗原的免疫治疗中也可能至关重要。
